Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02600130 · ClinicalTrials.gov registry record · Phase 1
Lomecel-B Infusion Versus Placebo in Patients With Alzheimer's Disease
A Phase 1 study, sponsored by Longeveron.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT02600130 is a Phase 1 study that has completed, run by Longeveron. The registered enrollment target is 33 participants.
The verdict
NCT02600130, a Phase 1 study, has completed, sponsored by Longeveron.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
This is a Phase I, prospective, randomized, placebo-controlled, double-blinded study designed to test the safety and efficacy of LMSCs (Longeveron Mesenchymal Stem Cells) for the treatment of subjects with clinically diagnosed Alzheimer's disease.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Longeveron Mesenchymal Stem Cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2016-10-10 |
| Est. Completion | 2021-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02600130
The ClinicalTrials.gov registry entry for NCT02600130 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Longeveron, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02600130 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02600130 about?
NCT02600130 is a clinical study titled "Lomecel-B Infusion Versus Placebo in Patients With Alzheimer's Disease". This is a Phase I, prospective, randomized, placebo-controlled, double-blinded study designed to test the safety and efficacy of LMSCs (Longeveron Mesenchymal Stem Cells) for the treatment of subjects with clinically diagnosed Alzheimer's disease.
What is the current status of trial NCT02600130?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2016-10-10. Estimated completion is 2021-09.
What interventions are being tested in trial NCT02600130?
The interventions under investigation include: Placebo (BIOLOGICAL), Longeveron Mesenchymal Stem Cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT02600130?
This trial is sponsored by Longeveron, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.